Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
Garrido-Castro, Ana (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica))
Saura, Cristina (SOLTI Breast Cancer Research Group, Barcelona)
Barroso-Sousa, Romualdo (Present Address: Hospital Sírio-Libanês, Brasilia, Brazil)
Guo, Hao (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Department of Data Sciences)
Ciruelos, Eva (Hospital Universitario 12 de Octubre (Madrid))
Bermejo, Begoña (Centro de Investigación Biomédica en Red de Cáncer)
Gavilá, Joaquin (Fundació Institut Valencià d'Oncologia)
Serra, Violeta (Vall d'Hebron Institut d'Oncologia)
Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Paré Brunet, Laia (SOLTI Breast Cancer Research Group)
Céliz, Pamela (SOLTI Breast Cancer Research Group)
Villagrasa, Patricia (SOLTI Breast Cancer Research Group)
Li, Yisheng (The University of Texas MD Anderson Cancer Center. Department of Biostatistics, Division of Basic Sciences)
Savoie, Jennifer (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica))
Xu, Zhan (Northern Arizona University. School of Communication)
Arteaga, Carlos L. (UT Southwestern Medical Center. Harold C. Simmons Comprehensive Cancer Center)
Krop, Ian E. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica))
Solit, David B. (Memorial Sloan Kettering Cancer Center)
Mills, Gordon B. (The University of Texas MD Anderson Cancer Center. Present Address: Division of Basic Science Research, Department of Systems Biology)
Cantley, Lewis C. (Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College)
Winer, Eric P. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica))
Lin, Nancy U. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica))
Rodon, Jordi (The University of Texas MD Anderson Cancer Center. Present Address: Department of Investigational Cancer Therapeutics)
Universitat Autònoma de Barcelona

Data:	2020
Resum:	Treatment options for triple-negative breast cancer remain limited. Activation of the PI3K pathway via loss of PTEN and/or INPP4B is common. Buparlisib is an orally bioavailable, pan-class I PI3K inhibitor. We evaluated the safety and efficacy of buparlisib in patients with metastatic triple-negative breast cancer. This was a single-arm phase 2 study enrolling patients with triple-negative metastatic breast cancer. Patients were treated with buparlisib at a starting dose of 100 mg daily. The primary endpoint was clinical benefit, defined as confirmed complete response (CR), partial response (PR), or stable disease (SD) for ≥ 4 months, per RECIST 1. 1. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and toxicity. A subset of patients underwent pre- and on-treatment tumor tissue biopsies for correlative studies. Fifty patients were enrolled. Median number of cycles was 2 (range 1-10). The clinical benefit rate was 12% (6 patients, all SD ≥ 4 months). Median PFS was 1. 8 months (95% confidence interval [CI] 1. 6-2. 3). Median OS was 11. 2 months (95% CI 6. 2-25). The most frequent adverse events were fatigue (58% all grades, 8% grade 3), nausea (34% all grades, none grade 3), hyperglycemia (34% all grades, 4% grade 3), and anorexia (30% all grades, 2% grade 3). Eighteen percent of patients experienced depression (12% grade 1, 6% grade 2) and anxiety (10% grade 1, 8% grade 2). Alterations in PIK3CA / AKT1 / PTEN were present in 6/27 patients with available targeted DNA sequencing (MSK-IMPACT), 3 of whom achieved SD as best overall response though none with clinical benefit ≥ 4 months. Of five patients with paired baseline and on-treatment biopsies, reverse phase protein arrays (RPPA) analysis demonstrated reduction of S6 phosphorylation in 2 of 3 patients who achieved SD, and in none of the patients with progressive disease. Buparlisib was associated with prolonged SD in a very small subset of patients with triple-negative breast cancer; however, no confirmed objective responses were observed. Downmodulation of key nodes in the PI3K pathway was observed in patients who achieved SD. PI3K pathway inhibition alone may be insufficient as a therapeutic strategy for triple-negative breast cancer. Registered on 13 February 2013; . Registered on 27 June 2012.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Buparlisib ; BKM120 ; Triple-negative breast cancer ; PI3K pathway ; Phase 1
Publicat a:	Breast cancer research, Vol. 22 (november 2020) , ISSN 1465-542X

DOI: 10.1186/s13058-020-01354-y
PMID: 33138866

13 p, 2.0 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats